Acute administration of metformin prior to cardiac ischemia/reperfusion injury protects brain injury

Myocardial ischemia is the malperfusion of cardiac tissue due to a blockage in a coronary artery. Subsequent return of blood flow to the ischemic area of the heart, results in ischemia/reperfusion (I/R) injury in the heart and other organs, including the brain. Besides the cardioprotective effects of metformin on the heart against cardiac I/R injury, metformin also reduced neuronal injury in a stroke model. However, the effects of metformin on the brain following cardiac I/R injury has not yet been investigated. Therefore, we hypothesize that metformin reduces brain damage via decreasing brain mitochondrial dysfunction, microglial hyperactivity, and Alzheimer's proteins in rats after cardiac I/R injury. Rats (n = 50) received either a sham operation (n = 10) or cardiac I/R (n = 40). Cardiac I/R was induced by 30 min of cardiac ischemia, followed by 120 min of reperfusion. Rats in cardiac I/R group were divided into 4 groups (n = 10/group); vehicle, metformin 100 mg/kg, metformin 200 mg/kg, and metformin 400 mg/kg. Metformin was given via femoral vein at 15 min prior to cardiac ischemia. At the end of reperfusion, brains were removed to determine dendritic spine density, brain mitochondrial function, microglial morphology, and amyloid beta formation. Cardiac I/R injury led to brain mitochondrial dysfunction, microglial hyperactivation, amyloid beta formation, Tau hyperphosphorylation, and reduced dendritic spine density with an increase in AMPK activation. All doses of metformin improved brain pathologies in rats with cardiac I/R injury possibly via activating cerebral AMPK. In summary, pre-treatment with metformin offers neuroprotection against the brain damages caused by cardiac I/R injury.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Myocardial ischemia is the malperfusion of cardiac tissue due to a blockage in a coronary artery.

Explore cómo esta investigación se conecta con la práctica clínica

More peer-reviewed studies in Desarrollo de fármacos.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)
• In-vitro antileishmanial potential of peptide drug hirudin — Khan H et al. (2017)
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines — Garcia DA, Baglin TP, Weitz JI, Samama MM (2012)
• Direct thrombin inhibitors — Lee CJ, Ansell JE (2011)
• Updates on Use and Monitoring of Direct Thrombin Inhibitors — Navaei A et al. (2026)

Browse all ASH-analysed research →